SCHEMBL4350336

SCHEMBL4350336

O=C1N=C(N2CCOCC2)SC1=Cc1ccc(OCc2ccccc2)c(OCc2ccccc2)c1

nearest known ligand 0.59

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.57
ALDH1A1 P00352 3/20 0.57
KDM4E B2RXH2 1/20 0.57
GAA P10253 1/20 0.57
GRIN1 Q05586 3/20 0.55
GRIN2B Q13224 3/20 0.55
MEN1 O00255 5/20 0.54
KMT2A Q03164 5/20 0.54
ADAMTS5 Q9UNA0 1/20 0.53
CYP1A2 P05177 2/20 0.53
CYP2C19 P33261 2/20 0.53
NPC1 O15118 1/20 0.53
RAB9A P51151 1/20 0.53
DCTPP1 Q9H773 1/20 0.53
MCHR1 Q99705 1/20 0.52
POLB P06746 1/20 0.52
HPGD P15428 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4350333 1.00 MAPT (0.57) MAPTALDH1A1KDM4EGAAGRIN1
SCHEMBL4350796 0.94 MEN1 (0.62) MAPTALDH1A1KDM4EGAAGRIN1
SCHEMBL4364812 0.94 MEN1 (0.62) MAPTALDH1A1KDM4EGAAGRIN1
SCHEMBL4350802 0.94 MEN1 (0.62) MAPTALDH1A1KDM4EGAAGRIN1
SCHEMBL4364816 0.94 MEN1 (0.62) MAPTALDH1A1KDM4EGAAGRIN1
SCHEMBL4358722 0.87 MAPT (0.68) MAPTALDH1A1KDM4EGAAGRIN1
SCHEMBL4358719 0.87 MAPT (0.68) MAPTALDH1A1KDM4EGAAGRIN1
SCHEMBL4359782 0.86 ALDH1A1 (0.57) MAPTALDH1A1KDM4EGAAGRIN1
SCHEMBL4359781 0.86 ALDH1A1 (0.57) MAPTALDH1A1KDM4EGAAGRIN1
SCHEMBL4147326 0.84 MCHR1 (0.77) MAPTALDH1A1GAAGRIN1GRIN2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1890695-B1 USE OF 2,5-DISUBSTITUTED THIAZOL-4-ONE DERIVATIVES IN DRUGS GRUENENTHAL GMBH (DE) 2013-02-20 EP claimed
US-20090215758-A1 Use of 2,5-Disubstituted Thiazol-4-One Derivatives in Drugs GRUENENTHAL GMBH (DE) 2009-08-27 US claimed
EP-1890695-B1 USE OF 2,5-DISUBSTITUTED THIAZOL-4-ONE DERIVATIVES IN DRUGS GRUENENTHAL GMBH (DE) 2013-02-20 EP disclosed
US-20090215758-A1 Use of 2,5-Disubstituted Thiazol-4-One Derivatives in Drugs GRUENENTHAL GMBH (DE) 2009-08-27 US disclosed
EP-1890695-A2 USE OF 2,5-DISUBSTITUTED THIAZOL-4-ONE DERIVATIVES IN DRUGS Grünenthal GmbH (DE) 2008-02-27 EP disclosed
WO-2006122777-A2 USE OF 2,5-DISUBSTITUTED THIAZOL-4-ONE DERIVATIVES IN DRUGS Grünenthal GmbH (DE) 2006-11-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215758-A1 Use of 2,5-Disubstituted Thiazol-4-One Derivatives in Drugs ABCB1, ABCG2, SLC5A2 MAPT 1470/4885ALDH1A1 284/4885KDM4E 3224/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.